Moreover, recent work in glioblastoma has revealed, not only that high levels of TRIB2 correlates with poor prognosis of patients with glioblastoma, but also that combined increased in TRIB2 and MAP3K is associated with resistance to temozolomide (TMZ) and radiotherapy [69], which are the standard of care for this tumour type. Here, TRIB2 is linked to neoplasm.